Business Description
![Innoveren Scientific Inc Innoveren Scientific Inc logo](https://static.gurufocus.com/logos/0C0000AQFI.png?14)
Innoveren Scientific Inc
NAICS : 541714
SIC : 2834
ISIN : US58504H1014
Description
Innoveren Scientific Inc Formerly H-CYTE Inc is a hybrid biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. It has two divisions: the Healthcare Medical Biosciences Division (which includes the Infusion Vertical and the Biologics Vertical) and the DenerveX medical device division.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.12 | |||||
Equity-to-Asset | -13.8 | |||||
Debt-to-Equity | -0.41 | |||||
Debt-to-EBITDA | -1.58 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -73.9 | |||||
3-Year EBITDA Growth Rate | 51.7 | |||||
3-Year EPS without NRI Growth Rate | 52.4 | |||||
3-Year FCF Growth Rate | 63 | |||||
3-Year Book Growth Rate | 44.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.32 | |||||
9-Day RSI | 53.58 | |||||
14-Day RSI | 55.76 | |||||
6-1 Month Momentum % | -86.72 | |||||
12-1 Month Momentum % | -99.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.08 | |||||
Quick Ratio | 0.08 | |||||
Cash Ratio | 0.06 | |||||
Days Payable | 383688 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -83.7 | |||||
Shareholder Yield % | -5846.52 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -202.65 | |||||
ROA % | -945.19 | |||||
ROIC % | -38.9 | |||||
ROC (Joel Greenblatt) % | -15005.32 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -1.54 | |||||
EV-to-EBITDA | -1.55 | |||||
EV-to-Revenue | 9.62 | |||||
EV-to-FCF | -4.75 | |||||
Earnings Yield (Greenblatt) % | -64.94 | |||||
FCF Yield % | -3991.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:IVRN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Innoveren Scientific Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.453 | ||
EPS (TTM) ($) | -4.33 | ||
Beta | 882.66 | ||
Volatility % | 99941.72 | ||
14-Day RSI | 55.76 | ||
14-Day ATR ($) | 0.000163 | ||
20-Day SMA ($) | 0.00469 | ||
12-1 Month Momentum % | -99.48 | ||
52-Week Range ($) | 0.0003 - 0.55 | ||
Shares Outstanding (Mil) | 4.66 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Innoveren Scientific Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Innoveren Scientific Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Innoveren Scientific Inc Frequently Asked Questions
What is Innoveren Scientific Inc(IVRN)'s stock price today?
The current price of IVRN is $0.01. The 52 week high of IVRN is $0.55 and 52 week low is $0.00.
When is next earnings date of Innoveren Scientific Inc(IVRN)?
The next earnings date of Innoveren Scientific Inc(IVRN) is .
Does Innoveren Scientific Inc(IVRN) pay dividends? If so, how much?
Innoveren Scientific Inc(IVRN) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |